ArticleACG case reports journal2026
The Tissue Systems Pathology Test Enabled Detection of Missed Prevalent High-Grade Dysplasia in a Presumed Clinically Low-Risk Patient With Nondysplastic Barrett's Esophagus.
Article in ACG case reports journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Clinical guidelines recommend the use of histopathology and segment length to risk stratify patients with Barrett's esophagus (BE), the only known precursor of esophageal adenocarcinoma (EAC). However, these clinicopathologic factors have limited ability to accurately identify patients with nondysplastic BE (NDBE) who may be at high risk of progression. The tissue systems pathology-9 (TSP-9) test (TissueCypher) is clinically validated to predict the risk of progression of BE to high-grade dysplasia (HGD) or EAC within 5 years. This case report highlights the clinical utility of TSP-9 test to identify high-risk patients with NDBE and inform shared decision making to prevent progression to HGD/EAC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.